Abstract
Objective To observe the effects of clopidogrel bisulfate on serum hs-CRP and soluble CD40 ligand ( sCD40L ) in patients with non-ST-segment elevation acute coronary syndromes ( NSTE-ACS ).Methods 40 patients with NSTE-ACS were randomly divided into control group ( 20 patients ) and clopidogrel bisulfate group ( 20 patients ).The latter group received oral clopidogrel at a loading dose of 300 mg on the first day and then 75 mg daily from the second day for 14 days in addition to conventional therapy.Enzyme-linked immunosorbent assay was used to measure serum levels of hsCRP and sCD40L in all the patients before and after treatment.Results After treatment,levels of hs-CRP and sCD40L were significantly decreased in both groups ( P＜ 0.05 ).The decreased levels of hs-CRP and sCD40L were more significant in the clopidogrel bisulfate group than in the control group ( P＜ 0.05 ).Conclusions Clopidogrel bisulfate combined with conventional therapy can significantly decrease serum levels of hs-CRP and sCD40L in patients with NSTE-ACS,effectively relieve inflammatory reaction of atherosclerosis,and reduce unstability of atheromatous plaque. Key words: Clopidogrel; Non-ST-segment elevation acute coronary syndromes; hs-CRP; sCD40L
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
